In fact, our multiple dose protocol shows that, not only in NGT but also in patients with T2D, during the IIGI the ß-cell responds to gradually increasing infused glucose loads with a progressive, commensurate increase in insulin secretion, such that the dose-response remains the same, or is even slightly shifted upward due to potentiation. This evidence concerns the gene INS and type 2 diabetes mellitus.